Adaptimmune Therapeutics Plc has appointed Elliot Norry as chief medical officer, a job that he has been doing on an interim basis since August 2019. He will lead development of the company’s immunotherapy treatments for cancer. Previously, Dr Norry was safety development leader at GlaxoSmithKline Plc. He holds a BA from Columbia College and a medical degree from New York University, both in the US.
Adaptimmune has also reorganised its R&D leadership team. Mark Dudley has become head of early stage product development; Dennis Williams, head of a late-stage development and Joanna Brewer, head of allogeneic cell therapy research.
Adaptimmune announced the appointments on 13 January 2020.
Copyright 2020 Evernow Publishing Ltd